Open Access

Targeting drug resistant stem cells in a human epidermal growth factor receptor‑2‑enriched breast cancer model

  • Authors:
    • Nitin Telang
  • View Affiliations

  • Published online on: April 11, 2019     https://doi.org/10.3892/wasj.2019.9
  • Pages: 86-91
  • Copyright: © Telang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Human epidermal growth factor receptor‑2 (HER‑2) expression in the presence or absence of hormone receptors dictates HER‑2‑targeted therapy with or without endocrine therapy. These treatment options lead to long‑term systemic toxicity, multi‑drug resistance and the emergence of therapy‑resistant cancer stem cells. These limitations emphasize the need for the development of reliable model systems with which to evaluate stem cell signaling molecules as testable targets for stem cell therapy, and to identify less toxic testable alternatives for therapeutic resistance. In this study, with the aim of identifying such a system, HER‑2‑positive tumorigenic 184‑B5/HER cells were used as a model of HER‑2‑enriched breast cancer. The epidermal growth factor receptor (EGFR)/HER‑2 specific small molecule inhibitor, lapatinib (LAP), was used to select the drug resistant phenotype. Vitamin A derivative, all trans‑retinoic acid (ATRA), and rosemary terpenoid carnosol (CSOL) represented the test agents. The LAP‑resistant (LAP‑R) phenotype exhibited an upregulated expression of select stem cell specific markers, including tumor spheroids, CD44, NANOG and Oct‑4. These data provide evidence for the effective development of a LAP‑R cancer stem cell model. ATRA and CSOL inhibited the expression of stem cell‑specific markers in the LAP‑R phenotype, suggesting that natural products may possess stem cell targeted therapeutic efficacy via the downregulation of select signaling molecules that are functional in cancer stem cells. On the whole, the findings of this study validate a cancer stem cell model which is able to identify natural products as testable alternatives for the treatment of therapy‑resistant HER‑2‑enriched breast cancer.

Related Articles

Journal Cover

March 2019
Volume 1 Issue 2

Print ISSN: 2632-2900
Online ISSN:2632-2919

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Telang, N. (2019). Targeting drug resistant stem cells in a human epidermal growth factor receptor‑2‑enriched breast cancer model . World Academy of Sciences Journal, 1, 86-91. https://doi.org/10.3892/wasj.2019.9
MLA
Telang, N."Targeting drug resistant stem cells in a human epidermal growth factor receptor‑2‑enriched breast cancer model ". World Academy of Sciences Journal 1.2 (2019): 86-91.
Chicago
Telang, N."Targeting drug resistant stem cells in a human epidermal growth factor receptor‑2‑enriched breast cancer model ". World Academy of Sciences Journal 1, no. 2 (2019): 86-91. https://doi.org/10.3892/wasj.2019.9